Approaches to improve photodynamic therapy of cancer

Firczuk, Małgorzata; Winiarska, Magdalena; Szokalska, Angelika; Jodlowska, Malgorzata; Swiech, Marta; Bojarczuk, Kamil; Salwa, Pawel; Nowis, Dominika

doi:10.2741/3684

Cited by 48 publications

(16 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, novel therapeutic strategies are needed to selectively induce the death of cancer cells while sparing normal cells. Recently, many attempts to improve the therapeutic effects of PDT have been reported (17) and several photosensitizers such as porfimer sodium (Photofrin), ALA and cisplatin have been used to enhance tumor cell death in PDT (18,19). In this study, we found that MB effectively sensitizes A549 human lung adenocarcinoma cells to PDT-induced apoptosis through caspase activation, downregulation of anti-apoptotic proteins, reduced MMP, activation of p38 signaling pathways and increased ROS.…”

Section: Discussionmentioning

confidence: 99%

Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells

et al. 2013

View full text Add to dashboard Cite

Combined treatment with a photosensitizer and iodide laser [photodynamic therapy (PDT)] has improved the outcome of various cancers. In this study, we investigated the effects of using the photosensitizer methylene blue (MB) in PDT in human lung adenocarcinoma cells. We found that MB enhances PDT-induced apoptosis in association with downregulation of anti-apoptotic proteins, reduced mitochondrial membrane potential (MMP), increased phosphorylation of the mitogen-activated protein kinase (MAPK) and the generation of reactive oxygen species (ROS). In MB-PDT-treated A549 cells, we observed PARP cleavage, procaspase-3 activation, downregulation of the anti-apoptotic proteins Bcl-2 and Mcl-1, and the reduction of mitochondrial membrane potential (MMP). Western blot data showed that phosphorylation of p38 was increased in MB-PDT-treated A549 cells, indicating that several signaling molecules participate in the apoptotic cascade. Our data also showed that apoptotic cell death in MB-PDT-treated cells occurred through a series of steps beginning with the photochemical generation of ROS. Demonstrating the role of ROS, pretreatment of A549 cells with the antioxidant N-acetylcysteine (NAC) followed by MB-PDT resulted in increased cell viability and reduced proteolytic cleavage of PARP.

show abstract

Section: Discussionmentioning

confidence: 99%

Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Usual curative treatments of solid tumors consist of systemic chemotherapy or radiotherapy combined with surgery, depending on the type, stage and localization of the tumor. Other treatment strategies, such as immunotherapy, hormonotherapy or photodynamic therapy are also used today to treat cancer through a systemic or local approach [3][4][5][6]. In spite of the progress that has been made in the field of cancer therapy, these current approaches are not yet satisfactory for many reasons.…”

Section: Introductionmentioning

confidence: 99%

In situ forming implants for local chemotherapy and hyperthermia of bone tumors

Mohamed

Borchard

Jordan

2012

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Hyperthermia, an established adjuvant in cancer treatment, potentiates the effects of anticancer drugs and synergetic combination can be obtained improving the therapeutic outcome. Bone metastases may benefit from this combination when treated through in situ forming implants. Once loaded with magnetizable (nano-) particles and antineoplastic agents, these implants allow for the local application of magnetically-induced hyperthermia and the release of an anticancer drug. The implant can be heated applying an external magnetic field, sensitizing the surrounding tumoral tissues, while releasing the chemotherapeutic agent.Moreover, bone implants provide mechanical support to the weakened bone and consequently relieve pain.This review gives an overview of the current knowledge as well as the rationale of combining locally both magnetic hyperthermia and chemotherapy using in situ forming implants in the field of bone metastases treatment. KeywordsInduced hyperthermia, chemotherapy, drug delivery systems, in situ forming implants, iron oxide nanoparticles, bone metastases, cementoplasty, vertebroplasty 3

show abstract

“…In addition, there are many clinical applications of PDT for treatment of a wide range of non-cancerous conditions, such as bacterial and fungal infections; hyperproliferative or inflammatory conditions, such as macular degeneration or psoriasis; and premalignant conditions, such as actinic keratosis [22] and Barrett's esophagus [23]. To achieve better therapeutic efficacy, new photosensitizers and novel light sources are continuously being developed, and the mechanisms of action are becoming better understood [24,25]. To achieve improved tumor selectivity and to reduce side effects in the treatment of cancer, the concept of targeted photodynamic therapy has been successfully developed by attaching specific functionalities to the photosensitizer, such as antibodies recognizing tumor antigens [26,27], or ligands and peptides to recognize receptors [28], which could be selectively expressed on one of the two major tumor compartments, either on the malignant cells or on tumor neovasculature.…”

mentioning

confidence: 99%

Photodynamic Therapy as an Emerging Treatment Modality for Cancer and Non-Cancer Diseases

Hu¹

2014

J Anal Bioanal Tech

View full text Add to dashboard Cite

Hu et al., J Anal Bioanal Tech 2014, S1 http://dx.doi.org/10.4172/2155-9872.S1-e001 ISSN: 2155-9872 JABT, an open access journal Photodynamic Therapy-Cancer J Anal Bioanal TechPhotodynamic therapy (PDT) is a treatment modality involving photoactivatable chemicals (called photosensitizers), light and tissue oxygen [1][2][3][4][5][6]. PDT has clinical applications in the treatment of a variety of solid cancers [4,7-21], including but not limited to those of lung, skin, breast, head and neck, digestive tract, pancreas, liver, bladder, ovary, prostate and brain. In addition, there are many clinical applications of PDT for treatment of a wide range of non-cancerous conditions, such as bacterial and fungal infections; hyperproliferative or inflammatory conditions, such as macular degeneration or psoriasis; and premalignant conditions, such as actinic keratosis [22] and Barrett's esophagus [23]. To achieve better therapeutic efficacy, new photosensitizers and novel light sources are continuously being developed, and the mechanisms of action are becoming better understood [24,25]. To achieve improved tumor selectivity and to reduce side effects in the treatment of cancer, the concept of targeted photodynamic therapy has been successfully developed by attaching specific functionalities to the photosensitizer, such as antibodies recognizing tumor antigens [26,27], or ligands and peptides to recognize receptors [28], which could be selectively expressed on one of the two major tumor compartments, either on the malignant cells or on tumor neovasculature. To achieve better efficacy than PDT that is targeted to a single tumor compartment (stPDT), a recent editorial [29] in this Journal summarized a new PDT approach (Figure 1), which was designed for dual targeting of photosensitizers (dtPDT) to both malignant cells and neovasculature [30,31] by conjugating photosensitizers to a protein, factor VII, the natural ligand for tissue factor. This approach allows for dual targeting of malignant cells and of tumor neovasculature, both of which either overexpress or selectively express tissue factor [30][31][32][33], respectively.In this special issue on PDT-Cancer, PDT scientists and experts worldwide contributed seven peer-reviewed articles. These review and research articles broadly cover the use and applications of PDT for cancer, for infections and for inflammatory conditions. Menon and Stafinski [34] in Canada thoroughly reviewed reports of clinical applications and clinical trials of PDT for the treatment of different types of cancers that were published in English between January 1997 and June 2011. They summarized a total of 266 studies, which involved 11,427 patients and 34 different types of cancer in diverse organs, such as anal and perianal cutaneous cancers, as well as cancers of the bile duct, bladder, brain, breast, cervical, esophageal, eye, gastrointestinal, head and neck, lung, peritoneal cavity, colorectal, liver, ovary, pancreas, prostate, skin, vulva, etc. Tsipursky, Churgin, Conway and Peyman [35] in the Uni...

show abstract

Approaches to improve photodynamic therapy of cancer

Cited by 48 publications

References 141 publications

Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells

Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells

In situ forming implants for local chemotherapy and hyperthermia of bone tumors

Photodynamic Therapy as an Emerging Treatment Modality for Cancer and Non-Cancer Diseases

Contact Info

Product

Resources

About